Published in J Clin Microbiol on June 26, 2013
Cross-reactivity profiles of hybrid capture II, cobas, and APTIMA human papillomavirus assays: split-sample study. BMC Cancer (2016) 0.81
A population-based observational study comparing Cervista and Hybrid Capture 2 methods: improved relative specificity of the Cervista assay by increasing its cut-off. BMC Infect Dis (2014) 0.78
CIN III lesions and regression: retrospective analysis of 635 cases. BMC Infect Dis (2015) 0.78
Determinants of viral oncogenes E6-E7 mRNA over-expression in a population-based large sample of women infected by high risk HPV types. J Clin Microbiol (2017) 0.75
Study-based evaluation of the Abbott RealTime High Risk HPV test in comparison to the HC2 HR HPV test in women aged ≥30 years using residual LBC ThinPrep specimens. BMC Infect Dis (2016) 0.75
Methylation analysis and HPV genotyping of self-collected cervical samples from women not responding to screening invitation and review of the literature. PLoS One (2017) 0.75
The changing culture of the microbiology laboratory. Can J Infect Dis Med Microbiol (2013) 0.75
A review of human carcinogens--Part B: biological agents. Lancet Oncol (2009) 13.85
Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med (2007) 9.53
Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol (2010) 7.29
GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J Clin Microbiol (2002) 5.63
HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol (2009) 4.99
The carcinogenicity of human papillomavirus types reflects viral evolution. Virology (2005) 4.72
Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting. J Natl Cancer Inst (2009) 3.71
Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer (2009) 3.64
Human papillomavirus genotype specificity of hybrid capture 2. J Clin Microbiol (2008) 2.51
Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst (2008) 2.36
Restricted cross-reactivity of hybrid capture 2 with nononcogenic human papillomavirus types. Cancer Epidemiol Biomarkers Prev (2002) 2.24
Comparison of PCR- and hybrid capture-based human papillomavirus detection systems using multiple cervical specimen collection strategies. J Clin Microbiol (1998) 2.21
Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J Natl Cancer Inst (2006) 2.16
Hybrid Capture II HPV Test detects at least 15 human papillomavirus genotypes not included in its current high-risk probe cocktail. J Clin Virol (2002) 2.05
Reproducibility of HPV DNA Testing by Hybrid Capture 2 in a Screening Setting. Am J Clin Pathol (2005) 1.80
Prevalence of type-specific HPV infection by age and grade of cervical cytology: data from the ARTISTIC trial. Br J Cancer (2008) 1.77
A comparison of a prototype PCR assay and hybrid capture 2 for detection of carcinogenic human papillomavirus DNA in women with equivocal or mildly abnormal papanicolaou smears. Am J Clin Pathol (2005) 1.73
Human papillomavirus testing in primary cervical screening and the cut-off level for hybrid capture 2 tests: systematic review. BMJ (2011) 1.72
Comparison of the SPF10-LiPA system to the Hybrid Capture 2 Assay for detection of carcinogenic human papillomavirus genotypes among 5,683 young women in Guanacaste, Costa Rica. J Clin Microbiol (2007) 1.64
Abundance of multiple high-risk human papillomavirus (HPV) infections found in cervical cells analyzed by use of an ultrasensitive HPV genotyping assay. J Clin Microbiol (2009) 1.55
Detection of high-risk HPV types by the hybrid capture 2 test. J Med Virol (2001) 1.49
Chapter 10: New dimensions in cervical cancer screening. Vaccine (2006) 1.46
Analytical comparison of the cobas HPV Test with Hybrid Capture 2 for the detection of high-risk HPV genotypes. J Mol Diagn (2011) 1.41
How to evaluate emerging technologies in cervical cancer screening? Int J Cancer (2009) 1.37
An analysis of high-risk human papillomavirus DNA-negative cervical precancers in the ASCUS-LSIL Triage Study (ALTS). Obstet Gynecol (2008) 1.26
The 2010 global proficiency study of human papillomavirus genotyping in vaccinology. J Clin Microbiol (2012) 1.24
Detection and quantitation of human papillomavirus DNA in the plasma of patients with cervical carcinoma. Cancer Epidemiol Biomarkers Prev (2002) 1.09
HPV prevalence and accuracy of HPV testing to detect high-grade cervical intraepithelial neoplasia. Int J Cancer (2011) 1.02
Hybrid capture-II and LCR-E7 PCR assays for HPV typing in cervical cytologic samples. Int J Cancer (2001) 1.01
Prevalence of human papillomavirus types in high-grade cervical intraepithelial neoplasia and cancer in Italy. Cancer Epidemiol Biomarkers Prev (2010) 1.00
The risk of false-positive histology according to the reason for colposcopy referral in cervical cancer screening: a blind revision of all histologic lesions found in the NTCC trial. Am J Clin Pathol (2008) 0.99
Analytical evaluation of the PapilloCheck test, a new commercial DNA chip for detection and genotyping of human papillomavirus. J Virol Methods (2008) 0.95
Complete genotyping of mucosal human papillomavirus using a restriction fragment length polymorphism analysis and an original typing algorithm. J Clin Virol (2008) 0.94
Resolving repeatedly borderline results of Hybrid Capture 2 HPV DNA Test using polymerase chain reaction and genotyping. J Virol Methods (2006) 0.91
Evaluation of HPV testing by Hybrid Capture II for routine gynecologic screening. Acta Obstet Gynecol Scand (2001) 0.91
Molecular epidemiology and pathogenic potential of underdiagnosed human papillomavirus types. BMC Microbiol (2008) 0.86
High genotyping concordance between the digene HPV Genotyping RH Test and the Reverse Line Blot genotyping assay on GP5+/6+-PCR products. J Clin Virol (2009) 0.83
Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol (2010) 7.29
Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine (2008) 4.82
Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer (2009) 3.64
Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer (2006) 3.38
Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine (2012) 3.09
Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. Lancet Oncol (2006) 2.59
Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst (2008) 2.36
Streptococcus pneumoniae in western Europe: serotype distribution and incidence in children less than 2 years old. Lancet Infect Dis (2006) 2.33
Four-year results of low-dose CT screening and nodule management in the ITALUNG trial. J Thorac Oncol (2013) 2.32
Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. Clin Cancer Res (2011) 2.27
Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial. Lancet Oncol (2008) 2.24
Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J Natl Cancer Inst (2006) 2.16
Screening patterns within organized programs and survival of Italian women with invasive cervical cancer. Prev Med (2013) 2.07
Actual and preferred place of death of cancer patients. Results from the Italian survey of the dying of cancer (ISDOC). J Epidemiol Community Health (2006) 2.06
Reproducibility of HPV DNA Testing by Hybrid Capture 2 in a Screening Setting. Am J Clin Pathol (2005) 1.80
Methods to increase participation in organised screening programs: a systematic review. BMC Public Health (2013) 1.71
EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease. Int J Cancer (2012) 1.63
Promoter methylation in APC, RUNX3, and GSTP1 and mortality in prostate cancer patients. J Clin Oncol (2009) 1.58
Chapter 10: New dimensions in cervical cancer screening. Vaccine (2006) 1.46
Eurogin 2010 roadmap on cervical cancer prevention. Int J Cancer (2011) 1.40
How to evaluate emerging technologies in cervical cancer screening? Int J Cancer (2009) 1.37
Reproductive factors, oral contraceptive use, and human papillomavirus infection: pooled analysis of the IARC HPV prevalence surveys. Cancer Epidemiol Biomarkers Prev (2006) 1.34
Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial. Lancet Oncol (2012) 1.29
Efficient DNA extraction from 25-year-old paraffin-embedded tissues: study of 365 samples. Pathology (2007) 1.28
TP53 codon 72 polymorphism and cervical cancer: a pooled analysis of individual data from 49 studies. Lancet Oncol (2009) 1.26
Cervical cancer screening policies and coverage in Europe. Eur J Cancer (2009) 1.23
Description of the national situation of cervical cancer screening in the member states of the European Union. Eur J Cancer (2009) 1.22
The immunochemical faecal occult blood test leads to higher compliance than the guaiac for colorectal cancer screening programmes: a cluster randomized controlled trial. J Med Screen (2005) 1.20
The role of GPs in increasing compliance to colorectal cancer screening: a randomised controlled trial (Italy). Cancer Causes Control (2006) 1.19
HPV triage for low grade (L-SIL) cytology is appropriate for women over 35 in mass cervical cancer screening using liquid based cytology. Eur J Cancer (2007) 1.15
Concurrent infections with multiple human papillomavirus (HPV) types in the New Technologies for Cervical Cancer (NTCC) screening study. Eur J Cancer (2011) 1.12
p16INK4a expression and progression risk of low-grade intraepithelial neoplasia of the cervix uteri. Virchows Arch (2004) 1.12
The reproducibility of CIN diagnoses among different pathologists: data from histology reviews from a multicenter randomized study. Am J Clin Pathol (2009) 1.10
Prevalence of HPV high and low risk types in cervical samples from the Italian general population: a population based study. BMC Infect Dis (2010) 1.08
Sensitivity, specificity, and clinical value of human papillomavirus (HPV) E6/E7 mRNA assay as a triage test for cervical cytology and HPV DNA test. J Clin Microbiol (2011) 1.06
The virtual slide in the promotion of cytologic and hystologic quality in oncologic screenings. Ann Ist Super Sanita (2010) 1.05
HPV prevalence and accuracy of HPV testing to detect high-grade cervical intraepithelial neoplasia. Int J Cancer (2011) 1.02
Association between hypermethylated tumor and paired surgical margins in head and neck squamous cell carcinomas. Clin Cancer Res (2007) 1.02
Mortality in elderly injured patients: the role of comorbidities. Int J Inj Contr Saf Promot (2008) 1.01
[Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors]. Epidemiol Prev (2012) 1.01
Prevalence of human papillomavirus types in high-grade cervical intraepithelial neoplasia and cancer in Italy. Cancer Epidemiol Biomarkers Prev (2010) 1.00
The risk of false-positive histology according to the reason for colposcopy referral in cervical cancer screening: a blind revision of all histologic lesions found in the NTCC trial. Am J Clin Pathol (2008) 0.99
Hypermethylation, risk factors, clinical characteristics, and survival in 235 patients with laryngeal and hypopharyngeal cancers. Cancer (2007) 0.97
miR-205 Expression levels in nonsmall cell lung cancer do not always distinguish adenocarcinomas from squamous cell carcinomas. Am J Surg Pathol (2011) 0.97
The clinical impact of using p16(INK4a) immunochemistry in cervical histopathology and cytology: an update of recent developments. Int J Cancer (2014) 0.96
Survey on colorectal cancer screening knowledge, attitudes, and practices of general practice physicians in Lazio, Italy. Prev Med (2004) 0.96
Occult HCV infection: an unexpected finding in a population unselected for hepatic disease. PLoS One (2009) 0.96
The seroepidemiology of human T-lymphotropic viruses: types I and II in Europe: a prospective study of pregnant women. J Acquir Immune Defic Syndr (2005) 0.95
A report on the current status of European research on the use of human papillomavirus testing for primary cervical cancer screening. Int J Cancer (2006) 0.95
Modelling patterns of clearance of HPV-16 infection and vaccination efficacy. Vaccine (2010) 0.95
Incidence of invasive cervical cancer and direct costs associated with its management in Italy. Tumori (2009) 0.93
Cost-effectiveness of vaccinating for invasive pneumococcal disease in the elderly in the Lazio region of Italy. Vaccine (2006) 0.93
Appropriateness of the indication for colonoscopy: is the endoscopist the 'gold standard'? J Clin Gastroenterol (2012) 0.93
HPV-16 infection and cervical cancer: modeling the influence of duration of infection and precancerous lesions. Epidemics (2010) 0.93
Prognostic significance of p53 and Ki-67 antigen expression in surgically treated non-small cell lung cancer: immunocytochemical detection with imprint cytology. Am J Clin Pathol (2006) 0.90
What's next? Perspectives and future needs of cervical screening in Europe in the era of molecular testing and vaccination. Eur J Cancer (2009) 0.90
Difference in overall and age-specific prevalence of high-risk human papillomavirus infection in Italy: evidence from NTCC trial. BMC Infect Dis (2013) 0.90
Road traffic injuries in one local health unit in the Lazio region: results of a surveillance system integrating police and health data. Int J Health Geogr (2009) 0.89
Cervical intraepithelial neoplasia and higher long term risk of cancer. BMJ (2007) 0.89
Distribution of high and low risk HPV types by cytological status: a population based study from Italy. Infect Agent Cancer (2011) 0.89
Defining a common set of indicators to monitor road accidents in the European Union. BMC Public Health (2006) 0.88
An emergency clinical pathway for stroke patients--results of a cluster randomised trial (isrctn41456865). BMC Health Serv Res (2009) 0.88
Effects of immigrant status on Emergency Room (ER) utilisation by children under age one: a population-based study in the province of Reggio Emilia (Italy). BMC Health Serv Res (2013) 0.88
Is human papillomavirus screening preferable to current policies in vaccinated and unvaccinated women? A cost-effectiveness analysis. J Med Screen (2010) 0.87
Physician and patient characteristics associated with prescriptions and costs of drugs in the Lazio region of Italy. Health Policy (2010) 0.87
Pediatrician-led motivational interviewing to treat overweight children: an RCT. Pediatrics (2013) 0.87
Is the type of test used for mass colorectal cancer screening a determinant of compliance? A cluster-randomized controlled trial comparing fecal occult blood testing with flexible sigmoidoscopy. Cancer Detect Prev (2006) 0.86
Interpretation of p16(INK4a) /Ki-67 dual immunostaining for the triage of human papillomavirus-positive women by experts and nonexperts in cervical cytology. Cancer Cytopathol (2014) 0.85
Persistent infection by HCV and EBV in peripheral blood mononuclear cells and risk of non-Hodgkin's lymphoma. Cancer Epidemiol (2010) 0.85
A cross-sectional study to estimate high-risk human papillomavirus prevalence and type distribution in Italian women aged 18-26 years. BMC Infect Dis (2013) 0.85
Triage of women with atypical squamous cells of undetermined significance (ASC-US): results of an Italian multicentric study. Gynecol Oncol (2010) 0.84